Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Trinity Biotech (TRIB) Accumulated Depreciation & Amortization (2023)

Trinity Biotech's Accumulated Depreciation & Amortization history spans 1 years, with the latest figure at $35.0 million for Q4 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $35.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $35.0 million, a N/A change, with the full-year FY2023 number at $35.0 million, changed N/A from a year prior.
  • Accumulated Depreciation & Amortization hit $35.0 million in Q4 2023 for Trinity Biotech.
  • Over the last five years, Accumulated Depreciation & Amortization for TRIB hit a ceiling of $35.0 million in Q4 2023 and a floor of $35.0 million in Q4 2023.